Advantages of digital PCR in the detection of low abundance BCR‑ABL1 gene in patients with chronic myeloid leukemia

Yan,Zhiling; Sun,Qian; Zhang,Huanxin; Han,Yahui; Qiao,Jianlin; Niu,Mingshan; Zhu,Shengyun; Zhao,Kai; Wu,Qingyun; Cheng,Hai; Cao,Jiang; Zeng,Lingyu; Li,Zhenyu; Xu,Kailin

doi:10.3892/ol.2019.10861

November-2019 Volume 18 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2019 Volume 18 Issue 5

Full Size Image

Article Open Access

Advantages of digital PCR in the detection of low abundance BCR‑ABL1 gene in patients with chronic myeloid leukemia

Authors:
- Zhiling Yan
- Qian Sun
- Huanxin Zhang
- Yahui Han
- Jianlin Qiao
- Mingshan Niu
- Shengyun Zhu
- Kai Zhao
- Qingyun Wu
- Hai Cheng
- Jiang Cao
- Lingyu Zeng
- Zhenyu Li
- Kailin Xu
View Affiliations / Copyright

Affiliations: Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China, Institute of Hematology, Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China

Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 5139-5144
|
Published online on: September 12, 2019

https://doi.org/10.3892/ol.2019.10861
Expand metrics +

Abstract

Quantitative monitoring of BCR‑ABL1IS gene using reverse transcription quantitative‑PCR (RT‑qPCR) is an important method for evaluating the treatment effects in patients with chronic myeloid leukemia (CML). Digital‑PCR (dPCR) can be applied to detect the BCR‑ABL1 gene with high sensitivity. In the present study, the results of the ClarityTM dPCR system were compared with those of the RT‑qPCR in order to determine whether dPCR can be applied in the clinical setting. A total of 83 patients were included in the present study, and they were divided into two groups according to the results of BCR‑ABL1IS during ongoing monitoring. A total of 43 patients with undetectable BCR‑ABL1IS where enrolled in group A. BCR‑ABL1 testing was performed using the dPCR system on the same peripheral blood samples of patients from group A, and the association between dPCR results and relapse was analyzed. The RT‑qPCR platform and dPCR system were used simultaneously to detect the BCR‑ABL1 gene of another 40 patients who achieved either partial cytogenetic response (PCyR) or further response. Among patients with undetectable BCR‑ABL1IS, patients with dPCR‑positive disease (BCR‑ABL1 >0.1%) were more likely to undergo molecular relapse (P=0.018). The results of dPCR detection of BCR‑ABL1% were consistent with the RT‑qPCR results (R2=0.9510) in patients who achieved PCyR or further response. For samples with BCR‑ABL1IS <1.0%, the consistency of the dPCR and RT‑qPCR results was better than that of BCR‑ABL1IS >1.0% (R2=0.9488 vs. R2=0.9264 for BCR‑ABL1IS). The detection results of the BCR‑ABL1 gene in patients with CML using dPCR matched well with those from the RT‑qPCR. To conclude, the results of the dPCR system can be applied as a supplement to the RT‑qPCR platform, particularly for those with BCR‑ABL1IS <1.0%.

View Figures

View References

1	Apperley JF: Chronic myeloid leukaemia. Lancet. 385:1447–1459. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, et al: Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 29:999–1003. 2015. View Article : Google Scholar : PubMed/NCBI
3	Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, et al: NCCN guidelines insights: Chronic myeloid leukemia, version 1.2017. J Natl Compr Canc Netw. 14:1505–1512. 2016. View Article : Google Scholar : PubMed/NCBI
4	Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, Goldman J and Hughes T: Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 20:1925–1930. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ramsden SC, Daly S, Geilenkeuser WJ, Duncan G, Hermitte F, Marubini E, Neumaier M, Orlando C, Palicka V, Paradiso A, et al: EQUAL-quant: An international external quality assessment scheme for real-time PCR. Clin Chem. 52:1584–1591. 2006. View Article : Google Scholar : PubMed/NCBI
6	Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH and Kamel-Reid S; Association for Molecular Pathology Hematopathology Subdivision, : Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: Summary and recommendations. J Mol Diagn. 9:421–430. 2007. View Article : Google Scholar : PubMed/NCBI
7	Alikian M, Whale AS, Akiki S, Piechocki K, Torrado C, Myint T, Cowen S, Griffiths M, Reid AG, Apperley J, et al: RT-qPCR and RT-digital PCR: A comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem. 63:525–531. 2017. View Article : Google Scholar : PubMed/NCBI
8	Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, et al: Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 112:3330–3338. 2008. View Article : Google Scholar : PubMed/NCBI
9	Foskett P, Gerrard G and Foroni L: Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia. Methods Mol Biol. 1160:115–124. 2014. View Article : Google Scholar : PubMed/NCBI
10	Huggett JF, Cowen S and Foy CA: Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem. 61:79–88. 2015. View Article : Google Scholar : PubMed/NCBI
11	Whale AS, Cowen S, Foy CA and Huggett JF: Methods for applying accurate digital PCR analysis on low copy DNA samples. PLoS One. 8:e581772013. View Article : Google Scholar : PubMed/NCBI
12	Wang WJ, Zheng CF, Liu Z, Tan YH, Chen XH, Zhao BL, Li GX, Xu ZF, Ren FG, Zhang YF, et al: Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression. Eur J Haematol. 101:291–296. 2018. View Article : Google Scholar : PubMed/NCBI
13	Zagaria A, Anelli L, Coccaro N, Tota G, Casieri P, Cellamare A, Impera L, Brunetti C, Minervini A, Minervini CF, et al: BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: Biological features and molecular monitoring by droplet digital PCR. Virchows Arch. 467:357–363. 2015. View Article : Google Scholar : PubMed/NCBI
14	Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, Elena C, Pierri I, Assouline S, D'Emilio A, et al: Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study. Am J Hematol. 90:910–914. 2015. View Article : Google Scholar : PubMed/NCBI
15	Goh HG, Lin M, Fukushima T, Saglio G, Kim D, Choi SY, Kim SH, Lee J, Lee YS, Oh SM and Kim DW: Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 52:896–904. 2011. View Article : Google Scholar : PubMed/NCBI
16	Taylor SC, Laperriere G and Germain H: Droplet digital PCR versus RT-qPCR for gene expression analysis with low abundant targets: From variable nonsense to publication quality data. Sci Rep. 7:24092017. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Advantages of digital PCR in the detection of low abundance BCR‑ABL1 gene in patients with chronic myeloid leukemia

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles